Using Gallium-68-deferoxamine to visualize pulmonary Aspergillus infections

iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

This study is testing if a special imaging method using gallium-68-deferoxamine can help doctors better see and diagnose lung infections caused by Aspergillus in patients.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Radboud University Medical Center (Academic / other)
• Locations: 1 site (Nijmegen)
• Trial ID: NCT06244979 on ClinicalTrials.gov

What this trial studies

This is a single-center, open-label feasibility trial aimed at evaluating the use of gallium-68-deferoxamine PET/CT imaging for diagnosing pulmonary aspergillosis. The study involves a single visit where participants will undergo imaging to assess the effectiveness of this non-invasive method in visualizing Aspergillus infections. The approach leverages the unique properties of siderophores, which are crucial for the iron acquisition of pathogenic fungi, to enhance imaging accuracy. By potentially reducing the need for invasive diagnostic procedures, this study seeks to improve the management of patients with suspected pulmonary aspergillosis.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with suspected chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis.

Not a fit: Patients who are pregnant, have severe kidney dysfunction, or have been on antifungal treatment for more than 48 hours prior to the study will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a non-invasive diagnostic tool for detecting pulmonary Aspergillus infections, improving patient outcomes.

How similar studies have performed: Preclinical studies have shown promising results with similar imaging approaches, indicating potential for success in this novel application.

Eligibility criteria

Inclusion Criteria:

1. The patient is at least 18 years old on the day of inclusion.
2. The patient has suspected chronic pulmonary aspergillosis or ABPA.
3. There is no significant interference with standard care and follow-up.

Exclusion Criteria:

1. The patient is pregnant or planning on becoming pregnant.
2. The patient has severe kidney dysfunction with eGFR \< 30 ml/min/kg and/or receives dialysis.
3. The patient has (chronic) iron overload.
4. The patient has been receiving antifungal treatment for more than 48 hours prior to the study day.
5. The patient is not able to lie still in the scanner.

Where this trial is running

Nijmegen

• RadboudUMC — Nijmegen, Netherlands (Recruiting)

Study contacts

• Principal investigator: Roger Brüggemann, PhD — Radboud University Medical Center
• Study coordinator: Laura Michon

Conditions Pulmonary Aspergillosis; Chronic Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis